(Q34556944)

3 August 2017

title

Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis (English)

1 reference

3 August 2017

0 references

0 references

1 reference

1 reference

Michael B Stokes

1

0 references

author name string

Kirk Foster

2

1 reference

3 August 2017

Glen S Markowitz

3

1 reference

3 August 2017

Farhang Ebrahimi

4

1 reference

3 August 2017

William Hines

5

1 reference

3 August 2017

Darren Kaufman

6

1 reference

3 August 2017

Brooke Moore

7

1 reference

3 August 2017

Daniel Wolde

8

1 reference

3 August 2017

Vivette D D'Agati

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

19 April 2005

1 reference

Nephrology Dialysis Transplantation

3 August 2017

published in

1 reference

3 August 2017

volume

20

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

1400-1406

1 reference

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Safety of tumour necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFH832

21 January 2018

Identifiers

DOI

10.1093/NDT/GFH832

1 reference

3 August 2017

1 reference